Trial Profile
Phase I/II Study of the Combination of Dasatinib With Chemotherapy for High Risk Acute Myeloid Leukemia (AML) Patients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 18 Aug 2021 Status changed from completed to discontinued due to the budget issues, the study discontinued at Phase II.
- 04 May 2018 Status changed from active, no longer recruiting to completed.
- 08 May 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2018.